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ABSTRACT
Objectives. To investigate the preva-
lence of ultrasound (US) detectable 
inflammation in hips of patients with 
ankylosing spondylitis (AS) and the re-
lationship between US and measures of 
disease activity and severity.
Methods. Consecutive patients with 
AS attending the rheumatology units 
involved in this study were enrolled. 
Clinical and demographical data were 
recorded. US examination of bilateral 
hips was performed at the same time, 
evaluating anterior longitudinal scan 
to search for synovial hypertrophy 
(SH), joint effusion (JE) or power Dop-
pler (PD) positive synovitis.
Results. A total of 56 patients were 
included, median age (interquartile 
range, IQR) 49 (39, 59.5), median 
disease duration 98 (72, 204) months, 
80.3% were treated with TNF-α inhibi-
tors, median BASDAI 2.65 (1.96, 3.95), 
30.3% had hip tenderness. US JE was 
found in 26.7% of patients, US SH in 
16%, no patient had detectable PD. 
The concordance between clinical find-
ings and US abnormalities was moder-
ate, with a kappa of 0.44. Patients with 
detectable US abnormalities had high-
er median visual analogue scale (VAS) 
pain and C-reactive protein (CRP), 
while there was no significant associa-
tion with other measures of disease ac-
tivity and disability. In the subgroup of 
patients with no hip tenderness, US al-
terations were still significantly related 
to higher CRP levels, while in patients 
with hip tenderness and no US abnor-
malities CRP was not higher than in 
the asymptomatic patients.
Conclusions. US assessment of hip 
joint in AS patients can be considered 
of value, as suggested by the correla-
tion with relevant clinical and labora-
tory measures. In asymptomatic pa-
tients, US examination might provide 
further information on subclinical in-
volvement.
Introduction
Ankylosing spondylitis (AS) is a chron-
ic inflammatory disease that implies in-
flammatory involvement of joints and 
entheses. Its prevalence is similar to that 
of rheumatoid arthritis (0.5%) (1, 2); the 
disease has a slightly higher prevalence 
in males and is genetically related to the 
HLA B27 allele (3-5). The natural his-
tory of the disease implies persistent in-
flammation of the sacroiliac joints and 
the spine, leading to ankylosis of the 
areas involved and disability (6). The 
musculoskeletal manifestations of the 
disease include mainly inflammatory 
back pain, even if enthesal involvement 
and peripheral arthritis can also be de-
tected. In most cases, arthritis asym-
metrically involves the lower limbs (6). 
In this context, hip involvement is far 
from rare: up to 36% of patients experi-
ence hip involvement during the course 
of the disease, with 8% of subjects 
undergoing hip replacement, which is 
bilateral in 47% of cases, especially in 
patients with longer disease duration 
(7, 8). Among all possible peripheral 
joint involvement, clinical reports in-
dicate that hip involvement increases 
the burden of the disease, leading to a 
reduction in physical function and an 
increase in the Bath Ankylosing Spond-
ylitis Disease Activity Index (BAS-
DAI) and Bath Ankylosing Spondylitis 
Functional Index (BASFI) scores (7, 
9). Moreover, the involvement of the 
hip concerns a subset of patients with 
more severe disease that will more like-
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ly progress from a radiographic point of 
view at spine level (7).
Ultrasonography (US) has proven to be 
a useful tool in patients with AS (10). 
In particular, US has been mainly ap-
plied to detect peripheral enthesitis (11-
13) and sacroiliac joint involvement 
(14) proving to be more sensitive than 
clinical examination. US has also been 
used to assess the posterior sacroiliac 
ligaments (15), and to make US-guided 
injections in refractory enthesitis (16). 
To our knowledge, no specific studies 
have investigated the role of US hip ex-
amination in patients with AS. US has 
proven to be useful in the evaluation 
of the hip in patients with rheumatoid 
arthritis, and to be more sensitive than 
physical examination in the detection of 
inflammatory abnormalities in this site 
(17). Compared to magnetic resonance 
imaging (MRI) as reference standard, 
grey-scale (GS) examination on US 
showed a lower specificity in the detec-
tion of synovitis in patients with rheu-
matic diseases, but a good sensitivity 
(18). Moreover, based on the findings 
of a histopathological study, the quali-
tative assessment of increased synovial 
vascularity using power Doppler (PD) 
is considered reliable in the hip (19).
The aim of the present study was to as-
sess the hip joints in patients with AS 
using US, in order to detect the fre-
quency of joint abnormalities on GS 
and PD examination, and to cross-sec-
tionally evaluate their relationship with 
clinical measures of disease activity 
and severity.
Patients and methods
Consecutive patients from five rheuma-
tology units, with a diagnosis of AS ac-
cording to the modified New York Cri-
teria (20), were enrolled. On the same 
day, patients underwent clinical and US 
evaluations. From a clinical point of 
view, main demographic, clinical and 
laboratory findings were recorded. In 
particular, BASDAI (21), BASFI (22), 
Bath Ankylosing Spondylitis Metrol-
ogy Index (BASMI)(23), Bath Anky-
losing Spondylitis Global Score (BAS-
G) (24), Visual analogue Scale (VAS) 
pain, VAS Global Health (VAS GH), 
VAS Patient’s Global Assessment (VAS 
PGA) were calculated. The presence of 
hip tenderness on history or motion, 
the concomitant therapy, erythrocyte 
sedimentation rate (ESR)(<20 mm/h) 
and high sensitivity C-reactive protein 
(CRP)(<0.5 mg/dl) were recorded. 
Disability was also evaluated using 
the Health Assessment Questionnaire 
modified for spondyloarthropathies 
(HAQ-S) (25).
US was performed at each centre by a 
single experienced operator, who was 
blinded to the clinical and laboratory 
data, and involved bilateral hips. Be-
fore beginning the study, the scanning 
protocol and the scoring system were 
selected with an agreement of all the 
participating centres. The patients were 
placed in a supine position, with the hip 
joints in neutral position. US was per-
formed with a Logiq 9 machine (General 
Electrics Medical Systems, Milwaukee, 
WI) with a 6–8 MHz multi-frequency 
linear array transducer. A standardised 
longitudinal anatomic section plane 
along the neck of the femur was used to 
visualise the anterior capsule, in order 
to detect joint effusion (JE) or synovial 
hypertrophy (SH), according to the Eu-
ropean League Against Rheumatism 
guidelines (26). Synovial pathology 
was defined according to the Outcome 
Measures in Rheumatoid Arthritis Clin-
ical Trials (OMERACT) definitions 
(27). In particular, JE was defined as 
abnormal hypoechoic or anechoic, PD 
negative, intraarticular material that is 
displaceable and compressible; SH as 
abnormal hypoechoic intraarticular tis-
sue non-displaceable and poorly com-
pressible that might be PD positive. 
Both JE and SH were evaluated accord-
ing to a dichotomic score, as present or 
absent. The limit for normal hip dimen-
sion was defined according to Koski et 
al., with values ≥7 mm and a difference 
of 1 or more mm is suggestive of intrac-
apsular effusion (28). JE and SH were 
also considered together, as presence 
or absence of US abnormalities at GS 
examination.
Synovial PD was assessed including 
an area  in the colour box that involved 
the joint and a variable view of the sur-
rounding tissues. Pulse repetition fre-
quency (PRF) was adjusted depending 
on the joint size at the lowest possible 
in order to maximise sensitivity, rang-
ing from 750 to 1100 Hz. Doppler fre-
quency was adjusted depending on pa-
tient’s characteristics and joint depth. 
Colour gain was set just below the level 
that causes the appearance of noise ar-
tefacts. Flow was demonstrated in two 
perpendicular planes and confirmed by 
pulsed wave Doppler spectrum to avoid 
artefacts. Synovial PD was evaluated as 
present or absent.
Statistical analysis
Descriptive results are reported as abso-
lute and relative frequency for categori-
cal data, and as median (IQR) or mean 
(SD) according to their distribution. 
Concordance between clinical and US 
hip involvement was calculated by over-
all agreement (percentage of observed 
exact agreement), and un-weighted ka-
ppa-statistics. 
The association between US involve-
ment and clinical variables was system-
atically investigated. Categorical vari-
ables was analysed using chi-squared 
tests, quantitative variables were ana-
lysed using the unpaired t-test for nor-
mally distributed, and Mann-Whitney 
U-test for non-normally distributed 
variables. 
The association between US and clini-
cal variables was also investigated in 
the subgroup of patients without clini-
cal hip involvement. 
All analyses were conducted using Sta-
ta, version 10 (StataCorp).
Results
A total of 56 patients were enrolled with 
a mean age (SD) of 49, of whom 35.7% 
were female and the median disease 
duration (interquartile range, IQR) was 
98 months (72–204). NSAIDs were 
used by 57.1% of the patients, while 
10.7% were taking steroids, however 
all of them at a low dose (≤5 mg/day). 
DMARDs were given to 33.9% of pa-
tients, in particular 26.8% were taking 
methotrexate (MTX) and 10.7% sul-
phasalazine (SSZ). A large proportion 
of patients (80.3%) were also treated 
with TNF-α inhibitors. Median BAS-
DAI (IQR) was 2.65 (1.96, 3.95), me-
dian BASMI (IQR) was 2 (1, 3), medi-
an BASFI (IQR) was 1.95 (0.72, 3.15), 
median BAS-G (IQR) 2.55 (1.5, 3.6). 
The median HAQ-S (IQR) was 0.7 
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(0.2, 1.8). Hip tenderness as revealed 
from the patient’s history or motion 
was reported by 17 (30.3%) patients. 
The demographical and clinical fea-
tures are summarised in Table I.
US examination demonstrated patho-
logical findings in 20 (37.5%) pa-
tients. In particular, JE was evident in 
15 (26.7%) subjects, while synovial 
hypertrophy was found in 9 (16%) pa-
tients. Synovial PD was not detected in 
any patient.
The concordance between clinical find-
ings (hip tenderness) and the detection 
by US of any hip abnormality meas-
ured by the kappa statistic, was moder-
ate, with a kappa of 0.44.
Afterwards, we investigated the rela-
tionship between clinical and demo-
graphical variables and US findings 
(Table II). Patients with US detectable 
hip involvement did not differ signifi-
cantly in terms of gender, age, disease 
duration, and ESR from patients with 
normal US findings. Nevertheless, 
CRP was higher in patients with US 
hip involvement, with a median (IQR) 
of 0.48 (0.2, 1.3) vs. 0.2 (0.1, 0.5) in 
patients with no US abnormalities 
(p=0.04). No differences were found 
between patients with US alterations 
in terms of BASDAI, BASFI, BASMI, 
BAS-G, HAQ-S, VAS GH, VAS PGA, 
while VAS pain (mm) was significantly 
higher in patients with US hip involve-
ment: a median (IQR) of 27 (4, 50) vs. 
10 (2, 30), p=0.03. There was no dif-
ference in the  number of tender and 
swollen joints.
To evaluate the additional value of US 
examination in asymptomatic patients, 
we then evaluated the data from pa-
tients who had no signs or symptoms 
of hip involvement. In this subgroup of 
patients, all the analysed variables did 
not significantly differ, except for CRP, 
which was still significantly higher in 
patients with US hip alterations (Table 
II). To further confirm the relevance of 
this finding, we performed the same 
analysis in patients with hip tenderness 
but no US alterations, and CRP was not 
higher in comparison with the patients 
with no symptoms (data not shown).
Discussion
US examination has proven to play an 
important role in the detection of many 
alterations in spondyloarthritides, with 
a greater sensitivity over clinical exam-
ination especially when applied to the 
investigation of sacroiliac joints and 
entheses (11, 14). The impact of US in 
the study of hip joints has not been spe-
cifically investigated so far.
Hip inflammation was reported to be 
a common manifestation in patients 
with AS (7, 29), with a large propor-
tion of patients experiencing this kind 
of involvement at least once during the 
course of the disease (6) In our popu-
lation, one third of patients reported 
symptoms that were compatible with 
joint inflammation, and US alterations 
were demonstrated in a similar propor-
tion of subjects, which is substantially 
consistent with the prevalence reported 
in the literature. In previous studies, 
hip involvement appeared to be more 
common in patients with longer dis-
ease duration, and its occurrence indi-
viduated a subgroup of patients with 
more severe disease, as suggested by 
the association with more extended 
axial involvement, and with worse 
BASDAI and BASFI scores (7). Nev-
ertheless, the relationship between US 
hip involvement and disease activity or 
physical function was not evident in the 
cohort we examined. It must be under-
lined that our population was mainly 
Table I. Demographical and clinical characteristics of the cohort. 
n.  56
Age (median, IQR)  49 (39, 59.5)
Male/female (n)  36/20
Disease duration (months)   98 (72, 204)
NSAIDs (n, %)  32 (57.14)
Steroids (n, %)  6 (10.71)
DMARDs (n, %)  19 (33.93)
 MTX (n, %) 15 (26.79)
 SSZ (n, %) 6 (10.71)
TNF-α inhibitors (n, %)  45 (80.36)
 Infliximab (n, %) 28 (50)
 Etanercept (n, %) 11 (19.64)
 Adalimumab (n, %) 6 (10.71)
 Golimumab (n, %) 2 (3.57)
ESR mm/h   18 (9.5, 24)
CRP mg/dl   0.3 (0.1, 0.66)
BASDAI   2.65 (1.96, 3.95)
BASFI   1.95 (0.72, 3.15)
BASMI   2 (1, 3)
BAS-G   2.55 (1.5, 3.6)
HAQ-S  0.7 (0.2, 1.2)
VAS pain (mm)  20 (3, 33.5)
VAS GH (mm)  65 (50, 88)
VAS PGA (mm)  10 (4, 45)
Swollen joint count   0 (0, 0)
Tender joint count   0 (0, 4)
Hip tenderness (n,%)  17 (30. 3)
US JE (n,%)  15 (26.78)
 Right hip (n,%) 13 (23.21)
 Left hip (n,%) 9 (16.07)
US SH (n,%)  9 (16.07)
 Right hip (n,%) 6 (10.71)
 Left hip (n,%) 6 (10.71)
US PD (n,%)  0 (0)
NSAIDs: non-steroidal anti-inflammatory drugs; DMARDs: disease-modifying anti-rheumatic drugs; 
ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; BASDAI: Bath Ankylosing Spond-
ylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; BASMI: Bath 
Ankylosing Spondylitis Metrology Index; BAS-G: Bath Ankylosing Spondylitis Global Health; HAQ-
S: Health assessment Questionnaire modified for spondyloarthropathies; VAS: visual analogue scale; 
GH: global health; PGA: patient’s global assessment; US JE: ultrasonographic joint effusion; US SH: 
ultrasonographic synovial hypertrophy; US PD: ultrasonographic power Doppler.
Values are expressed as median (IQR) unless otherwise specified.
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composed of patients with a long me-
dian disease duration, with the majority 
of subjects receiving active treatment 
such as TNF-α inhibitors, and low me-
dian BASDAI and BASFI. In this kind 
of population the prevalence of US ab-
normalities could be lower than in pa-
tients with active disease, and a larger 
sample size might have been necessary 
to detect a correlation with disease ac-
tivity and functional disability. In line 
with this supposition, in our patients 
increased  synovial vascularity detect-
ed by PD was not found in any patient. 
This is consistent with the results from 
a study on the effect of TNF-α blockers 
on synovial histology in patients with 
AS, which demonstrated a reduction in 
vascularity during treatment (30).
The detection of hip US abnormalities 
on GS examination was related to a 
higher overall median VAS pain, which 
is, however, a relevant indicator of over-
all disease burden. Besides this patient-
reported outcome, SH and/or JE were 
also related to an objective measure of 
disease activity, such as CRP that was 
higher in patients with US-detectable 
pathology. This latter finding supports 
the validity of US hip examination in 
AS patients. Moreover, this is in keep-
ing with results of previous studies, 
indicating higher CRP levels in case of 
large joint involvement (31). 
US alterations, detectable on GS exami-
nation, had only a moderate concordance 
with clinical manifestations suggestive 
of inflammatory hip involvement, as 
determined with kappa statistics. For 
this reason, a higher prevalence of US 
abnormalities in symptomatic patients 
should not be expected.
However, to explore the additional 
value of US examination in patients 
with no clinical signs and symptoms 
of inflammatory hip involvement, we 
performed a separate analysis in this 
subgroup. While US findings were not 
significantly related to clinical features, 
disease activity or disability, CRP was 
still significantly higher in subjects with 
US abnormalities, despite the small 
sample size, thus providing a further 
confirmation of the robustness of this 
finding. On the other hand, patients with 
hip tenderness and no US detectable in-
volvement did not show higher levels of 
Table II. Correlation between US and clinical features.
 
 All patients (n=56) Patients with no hip tenderness (n=39)
 
 US neg US pos p-value US neg US pos p-value
Age (years) 46 (38, 60) 53 (41, 59) 0.53 42 (36, 59) 43.5 (38.5, 48.5) 0.56
Disease duration (months) 102 (72, 192) 84 (72, 216) 0.52 96 (72, 148) 110 (78, 240) 0.43
ESR (mm/h) 18 (8,21) 19 (15, 32) 0.06 18 (6, 21) 18 (14, 20) 0.63
CRP (mg/dl) 0.2 (0.1, 0.5) 0.48 (0.2, 1.3) 0.04 0.2 (0.1, 0.4) 0.39 (0.3, 0.9) 0.02
BASDAI 2.6 (2.08, 3.8) 3 (1.6, 5.1) 0.40 2.7 (1.5, 3.8) 1.76 (0.79, 2.29) 0.18
BASFI 1.91 (0.6, 2.63) 2 (1, 3.9) 0.13 2 (0.55, 3) 1.17 (0.52, 1.67) 0.25
BASMI 2 (1,3) 3 (0,4) 0.27 1 (1, 2) 1 (1, 4) 0.92
BAS-G 2.6 (1.5, 3.5) 2.5 (1.5, 5.2) 0.30 2.1 (0.75, 3) 2 (0, 2.87) 0.61
HAQ-S 0.5 (0,1) 1 (0.25, 2.15) 0.13 0.4 (0, 1) 0.2 (0.2, 0.4) 0.90
VAS pain (mm) 10 (2, 30) 27 (4, 50) 0.03 10 (1, 30) 26 (17, 34) 0.11
VAS GH (mm) 70 (52, 90) 55 (40,70) 0.12 80 (65, 91) 69 (60, 92) 0.59
VAS PGA (mm) 10 (6, 35) 29 (4, 45) 0.68 10 (4, 30) 29 (5, 31) 0.48
Swollen joints 0 (0, 0) 0 (0, 0) 0.52 0 (0, 0) 0 (0, 0) n.a.
Tender joints 0 (0, 1) 2 (0, 4) 0.07 0 (0, 0) 0 (0, 2) 0.71
ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing 
Spondylitis Functional Index; BASMI: Bath Ankylosing Spondylitis Metrology Index; BAS-G: Bath Ankylosing Spondylitis Global Health; HAQ-S: Health 
assessment Questionnaire modified for spondyloarthropathies; VAS: visual analogue scale; GH: global health; PGA: patient’s global assessment.
Values are expressed as median (IQR) unless otherwise specified.
Fig. 1. Ultrasound images 
obtained using anterior lon-
gitudinal view in a patient 
with ankylosing spondylitis. 
A. Representative example of 
sonographic evidence of hip 
joint effusion (*). 
B. Contralateral side showing 
no signs of hip joint inflamma-
tion. f = femur. 
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CRP. Applied in a clinical setting, these 
results indicate that performing hip US 
in asymptomatic patients, especially 
when CRP is higher, might be helpful 
to detect local subclinical disease activ-
ity. Isolated hip tenderness seems to be 
a non-specific symptom that might also 
be due to consequences of past disease 
activity, such as secondary osteoarthri-
tis, more than to disease activity.
This study carries some limitations. 
The small sample size affects the pow-
er of the estimates, and the cross-sec-
tional design does not allow an evalu-
ation of the impact of US findings on 
relevant outcomes. Univariate analysis 
does not allow correction for possible 
confounders. However, to our knowl-
edge, this was the first study that spe-
cifically investigated the role of hip US 
in AS patients. Studies on larger popu-
lations and with longitudinal design 
will be helpful to clarify the role of this 
technique to detect a potentially severe 
manifestation of AS.
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